Scarica l'app Stockscreener
341.64
3.47%
11.47
Pre-mercato:
338.60
-3.04
-0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$330.17
Aprire:
$332.1
Volume 24 ore:
3.60M
Relative Volume:
1.39
Capitalizzazione di mercato:
$183.97B
Reddito:
$35.89B
Utile/perdita netta:
$7.01B
Rapporto P/E:
26.41
EPS:
12.9352
Flusso di cassa netto:
$11.54B
1 W Prestazione:
+4.38%
1M Prestazione:
+3.56%
6M Prestazione:
+16.62%
1 anno Prestazione:
+30.37%
Intervallo 1D:
$332.10
$343.05
Intervallo di 1 settimana:
$318.21
$343.05
Portata 52W:
$259.82
$346.38
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Confronta AMGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
341.64 | 177.79B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,108.09 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.49 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
233.42 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
141.98 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.60 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Evotec benefits from Dark Blue acquisition by Amgen - European Biotechnology Magazine
Amgen Inc.: How a Biotech Powerhouse Is Re-Architecting Its Drug Platform for the Next Decade - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Benjamin Edwards Inc. - MarketBeat
Call for Application for 2026 Tsinghua Amgen Scholars Program - PR Newswire
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - PR Newswire
Amgen Inc.: How a Biotech Veteran Is Re?Engineering Its Own Future - AD HOC NEWS
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs - Benzinga
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial - TipRanks
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline - Finviz
UBS Raises Amgen (AMGN) Price Target to $380 and Upgrades to Buy - GuruFocus
Amgen acquires cancer drugmaker Dark Blue Therapeutics for up to $840 mn - ETPharma.com
Amgen buys Dark Blue Therapeutics in $840m oncology deal - Yahoo Finance
Robeco Institutional Asset Management B.V. Has $123.48 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
UBS assumes coverage on Amgen stock with Buy rating, $380 price target - Investing.com UK
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Cerity Partners LLC Sells 6,837 Shares of Amgen Inc. $AMGN - MarketBeat
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies - GlobeNewswire Inc.
CWA Asset Management Group LLC Sells 14,786 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Acquires Dark Blue in $840 Million Deal to Pursue Innovative Leukemia Treatments - Bitget
Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report - BioCentury
UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380 - GuruFocus
Amgen upgraded to buy at UBS on potential of MariTide, olpasiran - Seeking Alpha
Amgen Paints Pipeline Dark Blue In Acquisition of Small Molecule Developer - Citeline News & Insights
Amgen’s Own High Court Loss Cited in Pushback to Evenity Claims - Bloomberg Law News
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal - GuruFocus
Amgen swoops on UK cancer biotech in deal worth up to $840mn - Financial Times
Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive
$840 million Dark Blue buy hands Amgen AML drug - The Pharma Letter
Amgen buys UK biotech Dark Blue Therapeutics for up to $840m - Sharecast.com
Amgen to buy blood cancer biotech Dark Blue Therapeutics in $840M deal - Axios
Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - MarketScreener
Amgen adds preclinical cancer asset via $840M deal for Dark Blue Therapeutics - FirstWord Pharma
Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million - MarketScreener
Amgen (AMGN) Acquires Dark Blue Therapeutics for $840 Million - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million - Investing.com
Dark Blue Therapeutics acquired by Amgen for up to $840 million - MarketScreener
Amgen (AMGN) Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million By Investing.com - Investing.com Canada
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal - Nasdaq
New acute leukemia approach behind Amgen's $840M acquisition - Stock Titan
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE - PR Newswire
Amgen Buys Cancer Drug Developer Dark Blue in $840 Million Deal - Bloomberg.com
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease - BioSpace
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Amgen's Q4 2025 Earnings Report - Barchart.com
Commonwealth Equity Services LLC Has $105.58 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
D.A. Davidson & CO. Purchases 6,222 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.46%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):